Rubivirus

From MicrobeWiki, the student-edited microbiology resource
This is a curated page. Report corrections to Microbewiki.
University of Oklahoma Study Abroad Microbiology in Arezzo, Italy[1]



Scanning electron microscope image of Rubella virus. From: blog.cytalk.com [2]


Etiology/Bacteriology

Taxonomy


| Domain = Viruses
| Class = ssRNA viruses
| Order = ssRNA positive-strand viruses, no DNA stage
| Family = Togaviridae
| Genus = Rubivirus

NCBI: Taxonomy Genome: Rubivirus

Description

The Rubella Virus is a single-stranded, positive-sense RNA virus. The Rubella Virus is the only member of the genus Rubivirus within the Togaviradae family. There is only one serotype of the virus that can survive and replicate stably. (6) The virus causes a disease also commonly referred to as the "German Measles". (5) The only reservoir for the virus is in humans. The virus infects a human then can be spread through the secretions of the nasopharyngeal tract along with blood and urine. In children and adults, the disease only shows mild symptoms including a purpuric rash, arthralgia, and swollen lymph nodes.

Genome

The genome of the Rubella virus is made of 9,762 nucleotides. The genome encodes for 5 different proteins including: P90 and P150 which are both non-structural proteins and three virion proteins which include the capsid, E2 and E1 (Envelope Proteins). Although there is only a single serotype of the Rubella virus, there have been 2 different clades identified. The two clades are 90%-92% similar at the nucleotide level. (ABERNATHY)

Pathogenesis

Transmission

Rubella virus is transmitted through direct contact with respiratory fluid. (2) The virus initially infects the respiratory tract and begins the replication process in that location. (3) The virus is present in feces, blood, and nasopharyngeal mucous for up to seven days before signs of rash and up to seven days after signs of rash. The virus can still be spread person-to-person without signs of clinical infection. (8)

Infectious dose and Incubation Period

The Rubella virus is infective at a dose of 30 viral units injected under the skin, 10 viral units inhaled into the respiratory tract or 60 viral units via nasal drops. The incubation period for the virus is between 14 and 21 days. A rash will present approximately 14 days after infection. (10)

Epidemiology

During the pre-immunization era, Rubella Virus epidemics would take place about every 6 to 9 years greatly impacting the population.

Virulence Factors

E1 Protein

Clinical Features

Postnatal Infection

The rubella virus, when contracted postnatal, has very mild signs and symptoms. The disease begins with a purpuric rash that starts on the face, in most cases, and spreads to the rest of the body. (8) In children, the disease will typically only cause the rash but in adults the rubivirus can cause mild fever, throat pain, arthralgia and enlarged lymph nodes, in addition to the rash. (3) The rubella virus causes a specific type of rash called maculopapular, meaning small flat, red and raised spots. (4) Overall, there is mild concern in regards to the Rubella infection when introduced into a healthy child or adult. In utero, infection of the Rubella virus causes severe birth defects or miscarriage in 80-90% of the patients. (8)

Congenital Syndrome

Congenital Rubella Syndrome Rash
From: http://pathmicro.med.sc.edu/mhunt/rubella.htm

The Congenital Rubella Syndrome is contracted when the virus is engaged in utero within the first trimester of pregnancy. (8) The fetus is therefore infected by the virus. The pregnancy will either be miscarried or the baby will be born with developmental delays or defects. The severity of the complications depends upon the gestational age of the fetus at the time of infection. The gestational age of the fetus will also determine the organ system of the baby in which the virus attacks. The gestational age coincides with the developmental stage in which the fetus is going through. (3) The possible and most common birth defects include hearing loss, ductus arteriosis, psychomotor retardation, mental retardation, microcephaly, cataracts, glaucoma, retinopathy, microphthalmia, intrauterine growth retardation, thrombocytopenia purpura, hepatomegaly and splenomegaly. The baby will then still be infected after birth and can spread the viral infection for up to one year. A risk of other health complications can continue to develop as the baby progresses into childhood and even adulthood including diabetes mellitus, thyroid disfunction, growth hormone deficiency and vision problems. (3)

Diagnosis

Rubella virus can be diagnosed clinically via the presence of the rash and swollen lymph nodes. Further serological tests can be ran to determine the presence of certain IgM antibodies which indicate that the patient had been recently infected with the virus. Hemagglutinin inhibition, ELISA, and indirect immunofluorescent immunoassay can all be ran on a blood sample to determine the presence of the antibodies. In adults and children, the virus can be isolated from the mucous of the respiratory tract. In babies and children, the virus can be isolated from the mucous of the respiratory tract, urine, feces, and blood. The cultured samples can be tested for the presence of the virus via immunoperoxidase staining assay or virus interference. (1)

Treatment

Treatment has not been found to be effective against postnatal rubella infection. Signs and symptoms may be treated with acetaminophen to reduce pain. The rubella virus yields mild symptoms in children and adults that do not present the need for medical attention. Pregnant women must watch for signs and symptoms and act upon them immediately. Hyperimmune globulin can be administered to women in order to lessen the side effects of the virus and lower the risk of the fetus being infected. (11)

Prevention

Vaccination

In 1969, licensure was granted for several different live attenuated vaccines for the rubella virus in the United States. The most commonly used vaccine today is a live attenuated vaccine prepared from RA 27/3. The vaccine works by initiating a mild infection of Rubella virus in the patient which then leads to immunity. This vaccine is given in two doses. The vaccination is most often combined with live attenuated Measles and Mumps providing immunity for both in addition to the Rubella Virus. When administered in combination with the Measles and Mumps vaccinations, it is referred to as MMR. The vaccine can be administered beginning at the age of 12 months and then the second vaccination is given around the age of 5 years. The vaccination is recommended for all children but especially women of childbearing age due to the risks associated with getting infected during pregnancy. The vaccination should never be administered to a woman who is pregnant due to the risk that the virus could still infect the fetus and cause congenital rubella syndrome. (1)

Host Immune Response

References

1. Parkman PD. "Togaviruses: Rubella Virus". Baron S, editor. Medical Microbiology. 4th edition. Galveston (TX): University of Texas Medical Branch at Galveston; 1996. Chapter 55. <http://www.ncbi.nlm.nih.gov/books/NBK8200/>
2. Blackwell, L. "Togaviridae: Rubella Virus". 2000. < http://web.stanford.edu/group/virus/toga/2000/c.html>
3. Hunt, M. "Virology: Rubella (German Measles) Virus". Microbiology and Immunology Online: University of South Carolina School of Medicine. 2011. <http://pathmicro.med.sc.edu/mhunt/rubella.htm>
4. Best, J. "Pathogenesis of Rubella and Congenital Rubella". Emeritus Reader in Virology. King's College London. 2012. <http://www.sabin.org/sites/sabin.org/files/JennyBest.pdf>
5. Mangala Prasad V, Willows S, Rossmann M, et al. Rubella virus capsid protein structure and its role in virus assembly and infection. Proceedings Of The National Academy Of Sciences Of The United States Of America [serial online]. December 10, 2013;110(50):20105-20110. <http://www.pnas.org.ezproxy.lib.ou.edu/content/110/50/20105.full>
6. DuBois, R., Vaney, M., Tortorici, M., Kurdi, R., Barba-Spaeth, G., Krey, T., & Rey, F. (2013). Functional and evolutionary insight from the crystal structure of rubella virus protein E1. Nature, 493(7433), 552-556. doi:10.1038/nature11741
7. Abernathy, E. S., Hübschen, J. M., Muller, C. P., Li, J., Brown, D., Komase, K., & ... Triki, H. (2011). Status of Global Virologic Surveillance for Rubella Viruses. Journal Of Infectious Diseases, 204S524-S532. doi:10.1093/infdis/jir099
8. Edlich, R., Winters, K., Long III, W. (2005). Journal of Long-Term Effects of Medical Implants. "Rubella and Congenital Rubella (German Measles)". DOI: 10.1615/JLongTermEffMedImplants.v15.i3.80. pages 319-328 <http://www.dl.begellhouse.com/journals/1bef42082d7a0fdf,69622d0e4ea6cf4b,4fb4b32d494cf55c.html>
9. Ilkow, C. S., Willows, S. D., & Hobman, T. C. (2010). Rubella virus capsid protein: A small protein with big functions. Future Microbiology, 5(4), 571-84. doi:http://dx.doi.org/10.2217/fmb.10.27
10. Public Health Agency of Canada. "Rubella Virus". (2010). < http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/rub-eng.php#endnote6>
11. Diseases and Conditions: Rubella. "Treatment and drugs". (2011). Mayo Foundation for Medical Education and Research. <http://www.mayoclinic.org/diseases-conditions/rubella/basics/treatment/con-20020067>